Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program-Reference-Cited by-同舟云学术

Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program

Published:2018-04-24 Issue:6 Volume:9 Page:1312-1322
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Gani Linsey¹²^ORCID,Lau Eric²,Luk Andrea³^ORCID,Sobrepena Leorino⁴,Tran Quang Khanh⁵,Kesavadev Jothydev⁶,Jia Weiping⁷,Yu Weinan⁸,Tsang Chiu Chi⁹,Mukhopadhyay Monojitketan¹⁰,Jha Sujeet¹¹,Sheu Wayne¹²,Ho Yoon Kun¹³,Nguyen Thy Khue¹⁴,Ozaki Risa³,So Wing Yee³,Kwan Christine²,Fu Amy W C²,Mirasol Roberto¹⁵,Phatak Sanjeev Ratnakar¹⁶,Kumar Kanakatte Mylariah Prasanna¹⁷,Aravind Sosale¹⁸,Janakiraman Hari¹⁹,Chan Juliana C N²³,

Affiliation:

1. Changi General Hospital; Singapore

2. Asia Diabetes Foundation; Prince of Wales Hospital; Sha Tin Hong Kong

3. Department of Medicine and Therapeutics; Hong Kong Institute of Diabetes and Obesity; Prince of Wales Hospital; The Chinese University of Hong Kong; Sha Tin Hong Kong

4. Heart of Jesus Hospital; San Jose Philippines

5. Nguyen Tri Phuong Hospital; Ho Chi Minh Vietnam

6. Jothydev's Diabetes and Research Center; Thiruvananthapuram Kerala India

7. Shanghai Sixth People's Hospital; Shanghai China

8. Huaian Second People's Hospital; Jiangsu China

9. Alice Ho Nethersole Hospital; Tai Po Hong Kong

10. Dr. M. K. Mukhopadhyay's Diabetic Clinic; Kolkata West Bengal India

11. Max Super Specialty Hospital; New Delhi Delhi India

12. Taichung Veterans General Hospital; Taichung Taiwan

13. The Catholic University of Korea; Seoul Korea

14. Medic Medical Center; Ho Chi Minh Vietnam

15. Manila Doctors Hospital; Manila Philippines